Brevinin-2-related Peptide and its [D4K] Analogue Stimulate Insulin Release In Vitro and Improve Glucose Tolerance in Mice Fed a High Fat Diet

Abstract

The cationic, α-helical frog skin antimicrobial peptide B2RP (brevinin-2-related peptide) shows sequence similarity to antimicrobial peptides belonging to the brevinin-2 family, but lacks the C-terminal cyclic heptapeptide domain (Cys-Lys-Xaa₄-Cys). Synthetic B2RP produced a significant (p<0.05) stimulation of insulin release (148% of basal rate at a concentration of 1 μM with a maximum response of 222% of basal rate at a concentration of 3 μM) from BRIN-BD11 clonal β-cells without increasing the release of the cytosolic enzyme, lactate dehydrogenase. Increasing cationicity of B2RP while maintaining amphipathicity by the substitution Asp⁴ → Lys enhanced the insulin-releasing potency (137% of basal rate at a concentration of 0.3 μM; p<0.05) with no stimulation of lactate dehydrogenase release. In contrast, the L18K, and D4K, L18K analogues were toxic to the cells, and the K16A analogue, with increased amphipathicity and hydrophobicity, showed reduced potency. Administration of [D4K]B2RP (100 nmol/kg body weight) to mice fed a high fat diet to induce obesity and insulin-resistance significantly (p<0.05) enhanced insulin release and improved glucose tolerance during the 60-minute period following an intraperitoneal glucose load (18 mmol/kg body weight). B2RP shows potential for development into an agent for the treatment of type 2 diabetes.

Key words

incretin peptide - frog skin - type 2 diabetes

References

• 1 Hancock RE. Cationic peptides: effectors in innate immunity and novel antimicrobials.  Lancet Infect Dis. 2001;  1 156-164
• 2 Rinaldi AC. Antimicrobial peptides from amphibian skin: an expanding scenario.  Curr Opin Chem Biol. 2002;  6 799-804
• 3 Abdel-Wahab YH, Power GJ, Flatt PR, Woodhams DC, Rollins-Smith LA, Conlon JM. A peptide of the phylloseptin family from the skin of the frog Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing activity.  Peptides. 2008;  29 2136-2143
• 4 Conlon JM, Power GJ, Abdel-Wahab YH, Flatt PR, Jiansheng H, Coquet L, Leprince J, Jouenne T, Vaudry H. A potent, non-toxic insulin-releasing peptide isolated from an extract of the skin of the Asian frog, Hylarana güntheri (Anura:Ranidae).  Regul Pept. 2008;  151 153-159
• 5 Marenah L, Flatt PR, Orr DF, McClean S, Shaw C, Abdel-Wahab YHA. Brevinin-1 and multiple insulin-releasing peptides in the skin of frog Rana palustris.  J Endocrinol. 2004;  181 347-354
• 6 Marenah L, McClean S, Flatt PR, Orr DF, Shaw C, Abdel-Wahab YHA. Characterization of naturally occurring peptides in the skin secretion of Rana pipiens frog reveal pipinin-1 as the novel insulin releasing peptide.  Peptides. 2005;  26 2117-2123
• 7 Marenah L, Flatt PR, Orr DF, McClean S, Shaw C, Abdel-Wahab YHA. Skin secretions of Rana saharica frogs reveal antimicrobial peptides esculentins-1 and -1B and brevinins-1E and -2EC with novel insulin releasing activity.  J Endocrinol. 2006;  188 1-9
• 8 Abdel-Wahab YHA, Power GJ, Ng MT, Flatt PR, Conlon JM. Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys¹⁸]-substituted analogue.  Biol Chem. 2008;  389 143-148
• 9 Kim JH, Lee JO, Jung JH, Lee SK, You GY, Park SH, Kim HS. Gaegurin-6 stimulates insulin secretion through calcium influx in pancreatic beta Rin5mf cells.  Regul Pept. 2010;  159 123-128
• 10 Bevier CR, Sonnevend A, Kolodziejek J, Nowotny N, Nielsen PF, Conlon JM. Purification and characterization of antimicrobial peptides from the skin secretions of the mink frog Rana septentrionalis.  Comp Biochem Physiol. 2004;  139C 31-38
• 11 Conlon JM, Ahmed E, Condamine E. Antimicrobial properties of brevinin-2-related peptide and its analogs: Efficacy against multidrug-resistant Acinetobacter baumannii.  Chem Biol Drug Des. 2009;  74 488-493
• 12 Kyte J, Doolittle DF. A simple method for displaying the hydropathic character of a protein.  J Mol Biol. 1982;  157 105-132
• 13 McClenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O’Harte FP, Yoon TW, Swanston-Flatt SK, Flatt PR. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.  Diabetes. 1996;  45 1132-1140
• 14 McClenaghan NH, Flatt PR. Physiological and pharmacological regulation of insulin release: insights offered through exploitation of insulin-secreting cell lines.  Diabetes Obes Metab. 1999;  1 137-150
• 15 Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice.  Diabetologia. 1981;  20 573-577
• 16 Irwin N, McClean PL, Hunter K, Flatt PR. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice.  Diabetes Obes Metab. 2009;  11 603-610
• 17 Schiffer M, Edmundson AB. Use of helical wheels to represent the structures of proteins and to identify segments with helical potential.  Biophys J. 1967;  7 121-135
• 18 Olson L, Soto A, Knoop FC, Conlon JM. Pseudin-2: an antimicrobial peptide with low hemolytic activity from the skin of the paradoxical frog.  Biochem Biophys Res Commun. 2001;  288 1001-1005
• 19 Islam MS, du Loots T. Experimental rodent models of type 2 diabetes: a review.  Methods Find Exp Clin Pharmacol. 2009;  31 249-261
• 20 Zhang HJ, Zhou F, Ji BP, Li B, Luo YC, Yu HQ, Zhang GZ. Effects of fructose and/or fat in the diet on developing the type 2 diabetic-like syndrome in CD-1 mice.  Horm Metab Res. 2009;  41 40-45
• 21 Tahrani AA, Piya MK, Kennedy A, Barnett AH. Glycaemic control in type 2 diabetes: Targets and new therapies.  Pharmacol Ther. 2010;  125 328-361
• 22 Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.  J Biol Chem. 1992;  267 7402-7405
• 23 Egan JM, Clocquet AR, Elahi D. The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes.  J Clin Endocrinol Metab. 2002;  87 1282-1290
• 24 Barnett A. Exenatide.  Expert Opin Pharmacother. 2007;  8 2593-2608

Correspondence